Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.55 |
| ▸ | BRAF | P15056 | 8/20 | 0.49 |
| ▸ | RAF1 | P04049 | 7/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5571965 | 0.92 | BRAF (0.53) | MAPK14BRAFRAF1MAPK13PKM | |
| SCHEMBL5575766 | 0.90 | RAF1 (0.61) | MAPK14BRAFRAF1MAPK13NTRK1 | |
| SCHEMBL5576199 | 0.90 | RAF1 (0.58) | MAPK14RAF1MAPK13NTRK1ALDH1A1 | |
| SCHEMBL937126 | 0.82 | MAPK14 (0.49) | MAPK14BRAFRAF1NTRK1ALDH1A1 | |
| SCHEMBL668121 | 0.81 | MAPK14 (0.51) | MAPK14BRAFRAF1PKMKMT2A | |
| SCHEMBL667588 | 0.79 | RAF1 (0.72) | MAPK14RAF1MAPK13NTRK1ALDH1A1 | |
| SCHEMBL669081 | 0.79 | RAF1 (0.60) | MAPK14RAF1MAPK13KMT2ASMN1; SMN2 | |
| SCHEMBL938751 | 0.78 | RAF1 (0.80) | MAPK14BRAFRAF1MAPK13NTRK1 | |
| SCHEMBL937085 | 0.77 | LMNA (0.48) | RAF1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL668089 | 0.76 | MEN1 (0.63) | MAPK14BRAFRAF1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | DUMAS JACQUES (US) | 2012-06-14 | — | — | US | claimed |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2012-02-23 | — | — | US | claimed |
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | claimed |
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | claimed |
| JP-4403482-B2 | — | — | 2010-01-27 | — | — | JP | claimed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | claimed |
| EP-1041982-A4 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2006-06-14 | — | — | EP | claimed |
| EP-1047418-B1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER PHARMACEUTICALS CORP (US) | 2005-07-27 | — | — | EP | claimed |
| JP-2001526223-A | — | — | 2001-12-18 | — | — | JP | claimed |
| EP-1047418-A4 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER AG (US) | 2001-02-07 | — | — | EP | claimed |
| EP-1047418-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-11-02 | — | — | EP | claimed |
| EP-1041982-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999032106-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | claimed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | claimed |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2016-01-21 | — | — | US | disclosed |
| EP-1041982-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032106-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032111-A1 | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149706-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | MAPK14 31/4885BRAF 97/4885RAF1 155/4885 |
| US-20120046290-A1 | INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS | MAPK1, MAP3K1, MAP3K7 | MAPK14 31/4885BRAF 97/4885RAF1 155/4885 |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | MAPK14 445/4885BRAF 487/4885RAF1 867/4885 |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | MAPK14 445/4885BRAF 487/4885RAF1 867/4885 |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | MAPK14 127/4885BRAF 1/4885RAF1 2/4885 |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | MAPK14 445/4885BRAF 487/4885RAF1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.